S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:PODD

Insulet - PODD Price Target & Analyst Ratings

$311.29
-3.64 (-1.16%)
(As of 03/28/2023 04:33 PM ET)
Add
Compare
Today's Range
$309.71
▼
$316.23
50-Day Range
$276.36
▼
$326.03
52-Week Range
$181.00
▼
$326.74
Volume
280,385 shs
Average Volume
848,971 shs
Market Capitalization
$21.65 billion
P/E Ratio
5,188.17
Dividend Yield
N/A
Price Target
$317.82

Insulet Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 11 Analyst Ratings

Consensus Analyst Price Target

$317.82
2.10% Upside
High Prediction$350.00
Average Prediction$317.82
Low Prediction$260.00
TypeCurrent
3/28/22 to 3/28/23		1 Month Ago
2/26/22 to 2/26/23		3 Months Ago
12/28/21 to 12/28/22		1 Year Ago
3/28/21 to 3/28/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$317.82$317.82$307.15$298.45
Predicted Upside2.10% Upside19.48% Upside22.41% Upside17.23% Upside
Get Insulet Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

PODD Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PODD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Insulet Stock vs. The Competition

TypeInsuletMedical CompaniesS&P 500
Consensus Rating Score
2.55
2.64
2.47
Consensus RatingModerate BuyBuyHold
Predicted Upside2.10% Upside1,959.16% Upside22.38% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/24/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight$320.00 ➝ $325.00+8.83%
2/24/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$320.00 ➝ $334.00+12.24%
2/24/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$340.00 ➝ $350.00+17.62%
2/24/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$245.00 ➝ $292.00-1.88%
1/26/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoveragePeer Perform
12/12/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Joanne Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target$270.00 ➝ $330.00+9.16%
11/4/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Kyle Rose
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$290.00 ➝ $310.00+21.40%
11/4/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$285.00 ➝ $320.00+25.32%
11/4/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Overweight$235.00 ➝ $340.00+33.15%
10/12/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageHold$260.00+11.69%
5/6/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$357.00 ➝ $345.00+52.04%
3/2/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy ➝ Buy
2/2/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$325.00+31.01%
1/31/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeMarket Perform ➝ Outperform$300.00 ➝ $275.00+16.24%
12/7/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy
7/21/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$285.00 ➝ $310.00+13.59%
12/16/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral$255.00 ➝ $268.00+10.85%
8/7/2020Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetPositive ➝ Equal Weight$165.00 ➝ $230.00+4.35%
5/8/2020Cfra
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetSell$162.00 ➝ $179.00-18.26%
5/8/2020Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetHold$161.00 ➝ $195.00-12.83%
5/8/2020JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight$200.00 ➝ $235.00+4.91%
3/31/2020Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
(Data available from 3/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












PODD Price Target - Frequently Asked Questions

What is Insulet's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for Insulet stock is Moderate Buy based on the current 5 hold ratings and 6 buy ratings for PODD. The average twelve-month price prediction for Insulet is $317.82 with a high price target of $350.00 and a low price target of $260.00. Learn more on PODD's analyst rating history.

Do Wall Street analysts like Insulet more than its competitors?

Analysts like Insulet less than other Medical companies. The consensus rating for Insulet is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how PODD compares to other companies.

Does Insulet's stock price have much upside?

According to analysts, Insulet's stock has a predicted upside of 19.48% based on their 12-month price targets.

What analysts cover Insulet?

Insulet has been rated by Barclays, Morgan Stanley, Raymond James, Robert W. Baird, and Wolfe Research in the past 90 days.


Stock Ratings Reports and Tools

Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
Ratings for Popular Stocks:
This page (NASDAQ:PODD) was last updated on 3/28/2023 by MarketBeat.com Staff